Haemonetics Corporation
HAE · Price history
Price at last available close
$118.32
+$12.52 (+11.83%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Haemonetics Corporation
Primary reporting period: 2026-03-28 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains.
How they make money
Haemonetics generates revenue primarily through the sale of medical devices and associated single-use disposables, as well as software solutions. The company operates a razor-and-blade business model where the initial sale or placement of capital equipment creates a recurring revenue stream from the ongoing sale of proprietary disposables and software subscriptions used in plasma collection, blood centers, and hospital surgical suites.
Products & services
The company provides medical technology solutions including plasma collection devices and disposables, blood collection and processing systems for red cells and platelets, and hospital technologies for hemostasis management, cell salvage, and transfusion management.
Brands & revenue mix
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
Period ended 2026-03-28Source
Period ended 2026-03-28Source
Period ended 2026-03-28Source
Period ended 2026-03-28Source
Period ended 2026-03-28Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer types
Customer concentration
The company discloses that it has significant customer concentration, particularly within its Plasma segment, where a limited number of large plasma collection companies account for a substantial portion of total revenue.
Suppliers, materials & equipment
- Unnamed — The company relies on various third-party suppliers for raw materials, electronic components, and contract manufacturing services to produce its medical devices and disposables.Source
Competitors
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
29
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
58
Fair
Financial Strength
49
Business Quality / Moat
67
Management
71
Growth Quality
27
Risk / Durability
84
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
35
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
41/100
Building Historical Record
Model Score 41/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Insider activity signal is favorable
- •Recent buyback activity is present
- •M&A headline · Sep 15, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for HAE
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can HAE maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is HAE's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is HAE's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify HAE's current valuation?
Essential Investment Snapshot
Wall Street Score
29
Opportunity Score
35
Market Cap
$5.38B
P/E Ratio
51.1
EPS
$2.06
52-Week High
$110.45
52-Week Low
$47.75
Beta
0.54
Intrinsic Value
$36.09
Analyst Target
$118.00
Shares Outstanding
47.4M
Total Revenue
$1.35B
Total Debt
$1.17B
Dividend
No current dividend
Liquidation Value / Share
$17.68
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for HAE
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
M&A headline · Sep 15, 2026
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on HAE.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Strong market position in plasma collection technology.
- +Recurring revenue model from disposables.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −Dependence on a limited number of large customers in the Plasma segment.
- −Regulatory risks associated with medical device manufacturing and approval.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
29
Sep 28, 2026
Change
Unchanged
Current Score
29
Oct 1, 2026
Category Changes
HAE score was unchanged.
Projected Score
Projected Score
32
Projected Change
+2.8 points
Preliminary comparable-period financial changes suggest improvement of approximately 2.8 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$118.32
Model Intrinsic Value
$36.09
Difference
+$82.23
+227.8% vs IV
Margin of Safety
-227.8%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.35B | $1.33B | $1.36B | $1.31B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $576.2M | $590.4M | $582.3M | $597.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $775.8M | $743.6M | $778.5M | $711.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $59.5M | $59.8M | $69.4M | $63.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $449.9M | $442.4M | $422.1M | $420.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $530.1M | $502.2M | $556.7M | $547.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $261.2M | $312.4M | $356.0M | $295.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $245.7M | $241.4M | $221.8M | $164.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $30.6M | $28.7M | $9.7M | $13.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $130.4M | $128.0M | $212.1M | $151.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $34.1M | $30.7M | $44.4M | $34.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $96.3M | $97.3M | $167.7M | $117.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $2.06 | $2.05 | $3.31 | $2.32 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 45.36M | 47.18M | 50.33M | 50.71M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 45.70M | 47.35M | 50.73M | 51.40M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$339.4M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$0.72
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-4.1%
Cash Change
-23.7%
Margin Change
-0.9 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Margins contracted
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, EPS growth, debt levels. Pressure indicators included cash levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 5.6%. EPS increased 2.9%. Cash declined 23.7%. Total debt declined 4.1%. Net income margin declined by 0.9 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Rumor Mill · HAE
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial